Table 1. Baseline characteristics for all cirrhosis patients and stratified on Child Pugh class.
| Baseline characteristics | All patients with cirrhosis (n = 106) | Child-Pugh A (n = 52) | Child-Pugh B (n = 36) | Child-Pugh C (n = 18) | P-value | Healthy controls (n = 35) |
|---|---|---|---|---|---|---|
| Age (years, median/IQR) | 63 (53–70) | 66 (60–71) | 61 (52–71) | 52 (50–57) | <0.01 | 61 |
| Sex (men, N/%) | 68 (64%) | 32 (62%) | 23 (64%) | 13 (72%) | 0.80 | 21 (61%) |
| MELD-Na (median, IQR) | 12 (9–15) | 9 (7–12) | 14 (11–15) | 22 (19–23) | <0.01 | |
| BMI (kg/m2, median, (IQR)) | 27 (24–31) | 28 (24–33) | 26 (23–31) | 26 (23–29) | 0.18 | |
| %MAIT cells/T-cells (median/IQR) | 0.80 (0.29–2.01) | 0.89 (0.33–2.47) | 0.64 (0.27–1.85) | 0.89 (0.54–1.94) | 0.72 | 6.08 (4.12–9.19) |
| Compensated at baseline n (%) | 71 (67%) | 5 (10%) | 16 (44%) | 15 (83%) | <0.01 | |
| Cirrhosis etiology n (% of all patients and of each Child Pugh class) | 0.3 | |||||
| NAFLD | 14 (13%) | 10 (19%) | 4 (11%) | 0 | ||
| Alcohol | 53 (50%) | 20 (38%) | 19 (52%) | 14 (78%) | ||
| Hepatitis C | 16 (15%) | 11 (15%) | 5 (14%) | 0 | ||
| Autoimmune | 17 (16%) | 9 (17%) | 4 (11%) | 4 (22%) | ||
| Cryptogenic/other | 6 (6%) | 2 (4%) | 4 (11) | 0 | ||
| LAB | ||||||
| Bilirubin micromole/L (median/(IQR)) | 19 (10–39) | 11 (8–14) | 28 (18–39) | 63 (48–145) | <0.01 | |
| PK-INR (median/IQR) | 1.2 (1.1–1.4) | 1.1 (1.0–1.2) | 1.4 (1.2–1.5) | 1.7 (1.4–2.0) | <0.01 | |
| Albumin (median/IQR) | 32 (26–36) | 36 (34–39) | 28 (25–32) | 23.5 (20–27) | <0.01 | |
| Platelets (median/IQR) | 149 (101–195) | 166 (111–209) | 129 (91–180) | 139 (82–166) | 0.08 | |
| Leukocytes (median/IQR) | 6 (4.4-7-6) | 6.0 (4.7–6.9) | 5.8 (3.9–7.8) | 7.1 (4.9–8.2) | 0.46 | |
| Neutrophils (median/IQR) | 3.6 (2.3–4.7) | 3.6 (2.3–4.6) | 3.4 (2.1–4.6) | 4.0 (2.8–6.4) | 0.18 | |
| Ascites n (% of all patients and of each Child Pugh class) | <0.01 | |||||
| No ascites | 59 (56%) | 45 (86%) | 13 (36%) | 1 (6%) | ||
| Controlled by diuretics | 15 (14%) | 2 (4%) | 9 (25%) | 4 (22%) | ||
| Paracentesis or increased diuretics the 6 past months | 26 (25%) | 3 (6%) | 10 (28%) | 13 (72%) | ||
| TIPS | 6 (6%) | 2 (4%) | 4 (11%) | 0 | ||
| Encephalopathy n (% of all patients and of each Child Pugh class) | <0.01 | |||||
| No encephalopathy | 96 (91%) | 52 (100%) | 31 (86%) | 13 (72%) | ||
| Mild HE grade 1–2 | 9 (8%) | 0 | 5 (14%) | 4 (22%) | ||
| Severe HE grade 3–4 | 1 (<1%) | 0 | 0 | 1 (6%) | ||
| Varices n (% of all pat). | 0.11 | |||||
| No varices | 59 (56%) | 35 (67%) | 14 (40%) | 10 (56%) | ||
| Varices, no bleeding | 42 (40%) | 16 (31%) | 19 (54%) | 7 (39%) | ||
| Varices, bleeding within 6 months from baseline | 4 (4%) | 1 (2%) | 2 (6%) | 1 (5%) | ||
Abbreviations: MAIT cells mucosal-associated invariant T-cells, IQR interquartile range, MELD model of end-stage liver disease, NAFLD non-alcoholic fatty liver disease, TIPS trans-jugular intrahepatic portosystemic shunt, BMI body mass index, HE hepatic encephalopathy.